haloperidol has been researched along with Sex Disorders in 8 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment-resistant patients (133 men, 24 women) diagnosed with DSM-IV schizophrenia or schizoaffective disorder participated in a double-blind, randomized, 14-week trial comparing clozapine (N = 40), olanzapine (N = 39), risperidone (N = 41), and haloperidol (N = 37)." | 9.11 | Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. ( Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J, 2004) |
| " We conducted this 6-month, parallel-group study to prospectively investigate the effects of the dopamine agonist cabergoline on sexual dysfunction in clinically stable patients with schizophrenia (DSM-IV, AP 194) and hyperprolactinemia (PRL > 20 ng/ml for men and PRL > 25 ng/ml for women)." | 7.79 | Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients. ( Arvanitakis, P; Dimopoulou, K; Kalkavoura, CS; Lykouras, L; Michopoulos, I; Theodoropoulou, P; Tzebelikos, E, 2013) |
| "Our results support the previously reported positive impact of atypical antipsychotics, particularly olanzapine, in patients with schizophrenia." | 7.72 | Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. ( Bitter, I; Boland, J; Dossenbach, M; el Mahfoud Kessaci, M; Erol, A; Hodge, A; O'Halloran, RA; Shaheen, MO; Sunbol, MM, 2004) |
| "Outpatients with schizophrenia, who initiated or changed antipsychotic treatment, and entered this 3-year, prospective, observational study were classified according to the monotherapy prescribed at baseline: olanzapine (N=2638), risperidone (N=860), quetiapine (N=142) or haloperidol (N=188)." | 5.12 | Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. ( Akram, A; Anders, M; Araszkiewicz, A; Dossenbach, M; Dyachkova, Y; Khalil, A; McBride, M; Pecenak, J; Pirildar, S; Shakhnovich, T; Treuer, T, 2006) |
| "Treatment-resistant patients (133 men, 24 women) diagnosed with DSM-IV schizophrenia or schizoaffective disorder participated in a double-blind, randomized, 14-week trial comparing clozapine (N = 40), olanzapine (N = 39), risperidone (N = 41), and haloperidol (N = 37)." | 5.11 | Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. ( Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J, 2004) |
| " We conducted this 6-month, parallel-group study to prospectively investigate the effects of the dopamine agonist cabergoline on sexual dysfunction in clinically stable patients with schizophrenia (DSM-IV, AP 194) and hyperprolactinemia (PRL > 20 ng/ml for men and PRL > 25 ng/ml for women)." | 3.79 | Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients. ( Arvanitakis, P; Dimopoulou, K; Kalkavoura, CS; Lykouras, L; Michopoulos, I; Theodoropoulou, P; Tzebelikos, E, 2013) |
| "Our results support the previously reported positive impact of atypical antipsychotics, particularly olanzapine, in patients with schizophrenia." | 3.72 | Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. ( Bitter, I; Boland, J; Dossenbach, M; el Mahfoud Kessaci, M; Erol, A; Hodge, A; O'Halloran, RA; Shaheen, MO; Sunbol, MM, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kalkavoura, CS | 1 |
| Michopoulos, I | 1 |
| Arvanitakis, P | 1 |
| Theodoropoulou, P | 1 |
| Dimopoulou, K | 1 |
| Tzebelikos, E | 1 |
| Lykouras, L | 1 |
| Zhang, XR | 1 |
| Zhang, ZJ | 1 |
| Jenkins, TA | 1 |
| Cheng, WR | 1 |
| Reynolds, GP | 1 |
| Jhanjee, A | 1 |
| Anand, KS | 1 |
| Bajaj, BK | 1 |
| Volavka, J | 1 |
| Czobor, P | 1 |
| Cooper, TB | 1 |
| Sheitman, B | 1 |
| Lindenmayer, JP | 1 |
| Citrome, L | 1 |
| McEvoy, JP | 1 |
| Lieberman, JA | 1 |
| Dossenbach, M | 2 |
| Erol, A | 1 |
| el Mahfoud Kessaci, M | 1 |
| Shaheen, MO | 1 |
| Sunbol, MM | 1 |
| Boland, J | 1 |
| Hodge, A | 1 |
| O'Halloran, RA | 1 |
| Bitter, I | 1 |
| Dyachkova, Y | 1 |
| Pirildar, S | 1 |
| Anders, M | 1 |
| Khalil, A | 1 |
| Araszkiewicz, A | 1 |
| Shakhnovich, T | 1 |
| Akram, A | 1 |
| Pecenak, J | 1 |
| McBride, M | 1 |
| Treuer, T | 1 |
| Mullen, B | 1 |
| Brar, JS | 1 |
| Vagnucci, AH | 1 |
| Ganguli, R | 1 |
| Meco, G | 1 |
| Falaschi, P | 1 |
| Casacchia, M | 1 |
| Rocco, A | 1 |
| Petrini, P | 1 |
| Rosa, M | 1 |
| Agnoli, A | 1 |
2 trials available for haloperidol and Sex Disorders
| Article | Year |
|---|---|
Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Double-Bl | 2004 |
Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Female; Halo | 2006 |
6 other studies available for haloperidol and Sex Disorders
| Article | Year |
|---|---|
Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients.
Topics: Adult; Amisulpride; Antipsychotic Agents; Cabergoline; Diagnostic and Statistical Manual of Mental D | 2013 |
The dose-dependent effect of chronic administration of haloperidol, risperidone, and quetiapine on sexual behavior in the male rat.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Dibenzothiazepines; Disease Models, Animal; Dop | 2011 |
Hypersexual features in Huntington's disease.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Humans; Huntington Disease; Olanz | 2011 |
Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Diagnostic and Statistical Manual | 2004 |
Frequency of sexual dysfunctions in patients with schizophrenia on haloperidol, clozapine or risperidone.
Topics: Antipsychotic Agents; Clozapine; Female; Haloperidol; Humans; Male; Risperidone; Schizophrenia; Sexu | 2001 |
Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia.
Topics: Adolescent; Adult; Chronic Disease; Drug Tolerance; Erectile Dysfunction; Female; Haloperidol; Human | 1985 |